Gynecologic Oncology | Specialty

The OncLive Gynecologic Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of gynecologic cancers, including ovarian cancer, endometrial cancer, and uterine cancer, among others. This section features news articles, interviews with gynecologic oncologists in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in gynecologic cancers.

Extended Treatment Time With Bevacizumab Does Not Confer PFS Benefit in Ovarian Cancer

November 26th 2022

Increasing the duration of bevacizumab treatment in the frontline setting did not improve progression-free survival for patients with advanced ovarian cancer.

PDS0101 Plus Chemoradiation Elicits 100% ORR in High-Risk Locally Advanced Cervical Cancer

November 23rd 2022

PDS0101 given in conjunction with chemoradiation elicited an 100% overall response rate, along with tumor shrinkage greater than 60%, in 9 patients with high-risk, locally advanced cervical cancer, according to results of the phase 2 IMMUNOCERV trial.

Dr. Dottino on the Benefit of Early-Detection Screening in Endometrial Cancer

November 23rd 2022

Peter R. Dottino, MD, discusses the benefit of early-detection screening for endometrial cancer.

Immunotherapy and You: Understanding the PD-L1 Blockade

November 23rd 2022

In this fifth episode of OncChats: Immunotherapy and You, John Nakayama, MD, and Ali Amjad, MD, discuss PD-1 blockade, potential biomarkers of response to treatment with immunotherapy, and the potential for these agents in the neoadjuvant setting.

Dr. Salani on the Role of HER2 Expression in Advanced Uterine Serous Carcinoma

November 22nd 2022

Ritu Salani, MD, MBA, discusses the role of HER2 expression on treatment decisions in advanced uterine serous carcinomas.

European Commission Approves Cemiplimab for Recurrent or Metastatic Cervical Cancer

November 22nd 2022

The European Commission has approved cemiplimab-rwlc monotherapy for the treatment of adult patients with recurrent or metastatic cervical cancer who have progressed on or after platinum-based chemotherapy.

Fertility and Other Treatment Considerations for Patients With Advanced Endometrial Cancer

November 22nd 2022

The panel shares how they determine a treatment regimen for patients with advanced endometrial cancer taking into consideration fertility and family planning, hereditary conditions, and comorbidities.

Patient Profile Presentation: A 76-Year-Old Woman With Advanced Endometrial Cancer

November 22nd 2022

Kathleen Lutz, RN, NP-BC WH, presents a 76-year-old woman with advanced endometrial cancer, and the panel assesses the chosen treatment regimens.

Crane Helps Gynecologic Fellows Deliver Care in a Complicated Time

November 21st 2022

Dr Crane discusses why Atrium Health decided to launch a gyn onc fellowship, how she helps fellows navigate the current political landscape while maintaining high-level care, and how she tries to model a good work-life balance for her trainees.

Onatasertib Plus Toripalimab Elicits Early Responses in Relapsed/Metastatic Cervical Cancer

November 17th 2022

Onatasertib plus toripalimab elicited an objective response rate of 52.4% in patients with relapsed or metastatic cervical cancer, irrespective of PD-L1 expression.

Long-term Survival Data With Immunotherapy in Gynecologic Cancers

November 16th 2022

In this fourth episode of OncChats: Immunotherapy and You, John Nakayama, MD, and Ali Amjad, MD, highlight long-term survival data reported with immunotherapy approaches in patients with gynecologic cancers.

Dr. Binder on the Use of Immune Checkpoint Inhibitors in Endometrial Cancer Treatment

November 16th 2022

Pratibha Binder, MD, discusses how the introduction of novel immune checkpoint inhibitors into frontline treatment strategies could ameliorate unmet needs in endometrial cancer.

Dr. Salani on Updates in Treating Endometrial Cancer

November 15th 2022

Ritu Salani, MD, MBA, discusses updates in treating endometrial cancer.

FDA Approves First IHC Companion Diagnostic for Mirvetuximab Soravtansine in Ovarian Cancer

November 15th 2022

The FDA has approved the VENTANA FOLR1 RxDx assay, the first immunohistochemistry companion diagnostic test to help identify patients with epithelial ovarian cancer who are eligible for treatment with mirvetuximab soravtansine-gynx.

Dr. Matulonis on the FDA Approval of Mirvetuximab Soravtansine in Frα+ Platinum-resistant Ovarian Cancer

November 15th 2022

Ursula A. Matulonis, MD, discusses the significance of the FDA approval of mirvetuximab soravtansine-gynx in patients with folate receptor α–positive, platinum-resistant ovarian cancer.

Dr. Saenz on the Need for Ongoing Research Efforts in Cervical Cancer

November 14th 2022

Cheryl Saenz, MD, discusses the need for ongoing research efforts in cervical cancer.

PARP Maintenance Therapy Provides Varying Benefit in Advanced Ovarian Cancer

November 10th 2022

The benefit of PARP maintenance therapy for patients with advanced ovarian cancer differs depending on a number of factors, including the homologous recombination and BRCA mutation status of the tumor.

Immunotherapy and You: The 5 Cs in Gynecologic Cancer

November 9th 2022

In this third episode of OncChats: Immunotherapy and You, John Nakayama, MD, and Ali Amjad, MD, review the 5 C's to consider when conducting research in gynecologic cancers and beyond.

40th Annual CFS® Highlights New Frontiers in Cancer Care

November 9th 2022

The Chemotherapy Foundation Symposium® returns to New York City for its 40th annual meeting with a 3-day program that will deliver the latest updates across the gamut of oncology care.

Dr. Binder on Key Trials Improving the Treatment Landscape for Endometrial Cancer

November 3rd 2022

Pratibha Binder, MD, discusses key trials improving the array of treatment options for patients with endometrial cancer.